Two types of brain chondroitin sulfate proteoglycan: their distribution and possible functions in the rat embryo.
The distribution of neurocan-like and 6B4 proteoglycan-like immunoreactivities in the rat embryo was investigated from gestational days 10.5-15.5 with monoclonal antibody 1G2 or 6B4 that immunoreacted with neurocan and 6B4 proteoglycan, respectively. In the brain region, the leptomeningeal layer in the myelencephalon, metencephalon, diencephalon or telencephalon was first stained with monoclonal antibody 1G2 at embryonic day 12.5. In the spinal cord, monoclonal antibody 1G2 stained the regions corresponding to the boundary caps (designated the boundary caps) after embryonic day 11.5 and the roof plate after embryonic day 12.5. The intensity of staining in the boundary caps reached a maximum at embryonic day 13.5, at around the time when the axons from the dorsal root ganglia reach this region. However, the points of contact of the axons with the boundary caps were hardly stained. By contrast, the roof plate was most strongly and widely stained at embryonic day 14.5, at around the time when the axons enter the spinal cord. Western blotting of preparations from the spinal cord that included the boundary caps revealed the presence of neurocan in this region. Thus, it is likely that neurocan serves as a barrier molecule to regulate the direction of axonal growth from the dorsal root ganglia. By contrast, in addition to staining of the future brain and spinal cord, monoclonal antibody 6B4 stained the trigeminal and sympathetic ganglia in the rat embryo on and after embryonic day 12.5, as well as the vestibular, facial and dorsal root ganglia after embryonic day 12.5. In studies in tissue culture, monoclonal antibody 6B4 prevented the inhibitory effects of 6B4 proteoglycan on the proliferation of PC12D cells. No immunostaining with monoclonal antibody 6B4 was observed in cells that had incorporated bromodeoxyuridine in vivo. Possible functions of 6B4 proteoglycan in the rat embryo are discussed.
Katoh-Semba
R
R
Department of Perinatology, Institute for Developmental Research, Aichi Human Service Center, Kasugai, Japan. katohsemba@inst-hsc.pref.aichi.jp
Matsuda
M
M
Watanabe
E
E
Maeda
N
N
Oohira
A
A
D000818:Animals; D000911:Antibodies, Monoclonal; D015153:Blotting, Western; D001921:Brain / Q000196:embryology*; D001923:Brain Chemistry / Q000502:physiology*; D001973:Bromodeoxyuridine / Q000276:immunology; D011508:Chondroitin Sulfate Proteoglycans / Q000032:analysis* / Q000276:immunology; D005260:Female; D037181:Lectins, C-Type; D008297:Male; D009419:Nerve Tissue Proteins / Q000032:analysis / Q000276:immunology; D058580:Neurocan; D016716:PC12 Cells; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D012995:Solubility; D014726:Vestibular Nuclei / Q000737:chemistry
D000911:Antibodies, Monoclonal; D011508:Chondroitin Sulfate Proteoglycans; D037181:Lectins, C-Type; D009419:Nerve Tissue Proteins; D058580:Neurocan; C076817:NCAN protein, human; D001973:Bromodeoxyuridine